The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study-Reference-Cited by-同舟云学术

The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study

Published:2021-01-01 Issue:1 Volume:8 Page:
ISSN:2001-8525
Container-title:European Clinical Respiratory Journal
language:en
Short-container-title:European Clinical Respiratory Journal

Author:

Fjaellegaard Katrine¹²^ORCID,Koefod Petersen Jesper¹²,Andersen Gitte³,Biagini Matteo³,Bhatnagar Rahul⁴⁵,Laursen Christian B.⁶⁷,Clementsen Paul Frost⁸⁹¹⁰,Bodtger Uffe¹²⁸^ORCID

Affiliation:

1. Department of Respiratory Medicine, Zealand University Hospital Naestved, Naestved, Denmark

2. Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark

3. Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Denmark

4. Department of Respiratory Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol, UK

5. Academic Respiratory Unit, University of Bristol, Bristol, UK

6. Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark

7. Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark

8. Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark

9. Copenhagen Academy for Medical Education and Simulation (CAMES), Rigshospitalet, University of Copenhagen and the Capital Region of Denmark, Copenhagen, Denmark

10. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/20018525.2021.1984375

Reference35 articles.

1. Ferlay J, Lam F, Colombet M, et al. Global cancer observatory: cancer today. Lyon: Fr Int Agency Res Cancer; Published online 2018 [cited 2020 May 11]. Available from: https//gco.iarc.fr/today.

2. Epidemiology of Lung Cancer

3. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma

4. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of serous fluid volume on next-generation sequencing: a significant step forward for optimization of serous fluid sample collection;Journal of the American Society of Cytopathology;2024-07